As a Free StocksGuide user, you can view scores for all 7,016 stocks worldwide.
10 Analysts have issued a Mesoblast forecast:
10 Analysts have issued a Mesoblast forecast:
Jun '25 |
+/-
%
|
||
Revenue | 26 26 |
191%
191%
|
|
Gross Profit | 18 18 |
223%
223%
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -123 -123 |
23%
23%
|
Net Profit | -153 -153 |
16%
16%
|
In millions AUD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. Its medicines target cardiovascular diseases, spine orthopedic disorders, oncology and hematology, immune-mediated, and inflammatory diseases. The company was founded by Silviu Itescu on June 8, 2004 and is headquartered in Melbourne, Australia.
Head office | Australia |
CEO | Silviu Itescu |
Employees | 73 |
Founded | 2004 |
Website | www.mesoblast.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.